Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients-Reference-Cited by-同舟云学术

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Published:2020-06-25 Issue:1 Volume:8 Page:
ISSN:2050-7771
Container-title:Biomarker Research
language:en
Short-container-title:Biomark Res

Author:

Liu Si-Yang,Sun Hao,Zhou Jia-Ying,Jie Guang-Ling,Xie Zhi,Shao Yang,Zhang Xian,Ye Jun-Yi,Chen Chun-Xiang,Zhang Xu-Chao,Zhou Qing,Yang Jin-Ji,Wu Yi-Long^ORCID

Funder

the National Key R&D Program of China

Special Fund of Public Interest by National Health and Family Control Committee

Key Lab System Project of Guangdong Science and Technology Department and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer

Health Collaborative Innovation Major Project from Guangzhou Science and Technology Bureau

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry (medical),Clinical Biochemistry,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40364-020-00199-z.pdf

Reference26 articles.

1. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.

2. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer. N Engl J Med. 2018;378:2078–92.

3. Zhang C, Leighl NB, Wu YL, Zhong WZ. Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 2019;12:45.

4. Qiu Z, Chen Z, Zhang C, Zhong W. Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. Exp Hematol Oncol. 2019;8:19.

5. Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12:92.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy;Journal of Cancer Research and Clinical Oncology;2024-09-07

2. Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial;The Lancet Respiratory Medicine;2024-08

3. Drug development and evidence for lung cancer targeted therapy in Eastern Asia;The Lancet Regional Health - Western Pacific;2024-08

4. Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study;Journal of Thoracic Oncology;2024-08

5. Efficacy of first‐line immune checkpoint inhibitor and anti‐angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen‐mutant advanced non‐small‐cell lung cancer: a systematic review and network meta‐analysis;Thoracic Cancer;2024-07-31